View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 4, 2018

China: Enrolment rate soars in single-country trials

In China, the enrolment rate of single-country trials far exceeds that of multinational trials in every phase.

By GlobalData Healthcare

In China, the enrolment rate of single-country trials far exceeds that of multinational trials in every phase (Figure 1). GlobalData looked at trials between January 2001 and April 2018 and found the rate was 12 times higher in single-country trials in Phase II and seven times higher in Phase I and Phase III trials. The much higher enrolment rate in single-country trials can be attributed to the single regulatory and ethical authority, as well as the availability of subjects meeting the inclusion criteria for trials.

Figure 1: Enrolment rate by phase in multinational and single-country trials in China

Source: GlobalData                                                                                                                                                                                                    ©GlobalData

Related Companies

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU